|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics. 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stein U, Walther W, Arlt F, Schwabe H,
Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly
identified key regulator of HGF-MET signaling, predicts colon
cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Board RE and Valle JW: Metastatic
colorectal cancer: Current systemic treatment options. Drugs.
67:1851–1867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombet M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hansen JD, Kumar S, Lo WK, Poulsen DM,
Halai UA and Tater KC: Ursodiol and colorectal cancer or dysplasia
risk in primary sclerosing cholangitis and inflammatory bowel
disease: A meta-analysis. Dig Dis Sci. 58:3079–3087. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase Akt pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang SX, Polley E and Lipkowitz S: New
insights on PI3K/Akt pathway alterations and clinical outcomes in
breast cancer. Cancer Treat Rev. 45:87–96. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ciruelos Gil EM: Targeting the
PI3K/Akt/mTOR pathway in estrogen receptor-positive breast cancer.
Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Badve S and Nakshatri H: Role of Akt
isotypes in breast cancer. J Pathol. 229:e12013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Johnson SM, Gulhati P, Rampy BA, Han Y,
Rychahou PG, Doan HQ, Weiss HL and Evers BM: Novel expression
patterns of PI3K/Akt/mTOR signaling pathway components in
colorectal cancer. J Am Coll Surg. 210:767–778. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li Y, Dowbenko D and Lasky LA: AKT/PKB
phosphorylation of p21Cip/WAF1 enhances protein stability of
p21Cip/WAF1 and promotes cell survival. J Biol Chem.
277:11352–11361. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meng F and D'Mello SR: NF-kappaB
stimulates Akt phosphorylation and gene expression by distinct
signaling mechanisms. Biochim Biophys Acta. 1630:35–40. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saini KS, Loi S, de Azambuja E,
Metzger-Filho O, Saini ML, Ignatiadis M, Dancey JE and
Piccart-Gebhart MJ: Targeting the PI3K/Akt/mTOR and Raf/MEK/ERK
pathways in the treatment of breast cancer. Cancer Treat Rev.
39:935–946. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carriere A, Romeo Y, Acosta-Jaquez HA,
Moreau J, Bonneil E, Thibault P, Fingar DC and Roux PP: ERK1/2
phosphorylate Raptor to promote Ras-dependent activation of mTOR
complex 1 (mTORC1). J Biol Chem. 286:567–577. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Okkenhaug K, Graupera M and Vanhaesebroeck
B: Targeting PI3K in Cancer: Impact on tumor cells, their
protective Stroma, Angiogenesis, and Immunotherapy. Cancer Discov.
6:1090–1105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bader AG, Kang S, Zhao L and Vogt PK:
Oncogenic PI3K deregulates transcription and translation. Nat Rev
Cancer. 5:921–929. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee SH, Kim HS, Park WS, Kim SY, Lee KY,
Kim SH, Lee JY and Yoo NJ: Non-small cell lung cancers frequently
express phosphorylated Akt; an immunohistochemical study. APMIS.
110:587–592. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cappuzzo F, Magrini E, Ceresoli GL,
Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri
A, Damiani S, et al: Akt phosphorylation and gefitinib efficacy in
patients with advanced non-small-cell lung cancer. J Natl Cancer
Inst. 96:1133–1141. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khaleghpour K, Li Y, Banville D, Yu Z and
Shen SH: Involvement of the PI 3-kinase signaling pathway in
progression of colon adenocarcinoma. Carcinogenesis. 25:241–248.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Itoh N, Semba S, Ito M, Takeda H, Kawata S
and Yamakawa M: Phosphorylation of Akt/PKB is required for
suppression of cancer cell apoptosis and tumor progression in human
colorectal carcinoma. Cancer. 94:3127–3134. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Müller J, Ehlers A, Burkhardt L, Sirma H,
Steuber T, Graefen M, Sauter G, Minner S, Simon R, Schlomm T, et
al: Loss of pSer2448-mTOR expression is linked to adverse prognosis
and tumor progression in ERG-fusion-positive cancers. Int J Cancer.
132:1333–1340. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McKay JA, Douglas JJ, Ross VG, Curran S,
Murray GI, Cassidy J and McLeod HL: Cyclin D1 protein expression
and gene polymorphism in colorectal cancer. Aberdeen Colorectal
Initiative. Int J Cancer. 88:77–81. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Motohashi M, Wakui S, Muto T, Suzuki Y,
Shirai M, Takahashi H and Hano H: Cyclin D1/cdk4, estrogen
receptors α and β, in N-methyl-N'-nitro-N-nitrosoguanidine-induced
rat gastric carcinogenesis: Immunohistochemical study. J Toxicol
Sci. 36:373–378. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lee KH, Lee HE, Cho SJ, Cho YJ, Lee HS,
Kim JH, Nam SY, Chang MS, Kim WH and Lee BL: Immunohistochemical
analysis of cell cycle-related molecules in gastric carcinoma:
Prognostic significance, correlation with clinicopathological
parameters, proliferation and apoptosis. Pathobiology. 75:364–372.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weichert W, Boehm M, Gekeler V, Bahra M,
Langrehr J, Neuhaus P, Denkert C, Imre G, Weller C, Hofmann HP, et
al: High expression of RelA/p65 is associated with activation of
nuclear factor-kappaB-dependent signaling in pancreatic cancer and
marks a patient population with poor prognosis. Br J Cancer.
97:523–530. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Uzgare AR, Kaplan PJ and Greenberg NM:
Differential expression and/or activation of P38MAPK, erk1/2, and
jnk during the initiation and progression of prostate cancer.
Prostate. 55:128–139. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Noone AM, Schussler N, Negoita S, Adamo M,
Cronin K, Cyr J, Gress D, Grove C, Kosary C, Liu B, et al:
Availability of TNM staging data elements in the medical record and
training needs assessment: Results from the 2014 SEER Training
Needs Assessment for TNM study. J Registry Manag. 42:40–47.
2015.PubMed/NCBI
|
|
33
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lievre A, Bachet JB, Le Corre D, Boige V,
Landi B, Emile JF, Coté JF, Tomasic G, Penna C, Ducreux M, et al:
KRAS mutation status is predictive of response to cetuximab therapy
in colorectal cancer. Cancer Res. 66:3992–3995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Apple SK, Hecht JR, Lewin DN, Jahromi SA,
Grody WW and Nieberg RK: Immunohistochemical evaluation of K-ras,
p53, and HER-2/neu expression in hyperplastic, dysplastic, and
carcinomatous lesions of the pancreas: Evidence for multistep
carcinogenesis. Hum Pathol. 30:123–129. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Poulikakos PI and Solit DB: Resistance to
MEK inhibitors: Should we co-target upstream? Sci Signal.
4:pe162011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Branca M, Ciotti M, Santini D, Bonito LD,
Benedetto A, Giorgi C, Paba P, Favalli C, Costa S, Agarossi A, et
al: Activation of the ERK/MAP kinase pathway in cervical
intraepithelial neoplasia is related to grade of the lesion but not
to high-risk human papillomavirus, virus clearance, or prognosis in
cervical cancer. Am J Clin Pathol. 122:902–911. 2004. View Article : Google Scholar : PubMed/NCBI
|
